The Use of a Recombinant DNA-based Hyaluronidase to Dissolve Fixed Amounts of Hyaluronic Acid Dermal Fillers

NCT02654522 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Dermal Filler

Interventions

DRUG: Hylenex

Sponsor

Steve Yoelin M.D. Medical Associates, Inc.